Expanded access to nanobubble oxygen therapy for serious conditions
Part of Brain & nervous system, Cancer, Heart & circulation clinical trials.
This program gives patients with serious, life-threatening conditions access to an experimental oxygen treatment called NanO2 when no other options are left. It may provide a chance to benefit when standard treatments have failed or are not available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your condition is serious or immediately life-threatening.
- You have already tried all other available treatments, or you are not able to join any ongoing clinical trials.
- Your doctor and the company believe that the possible benefit of this treatment outweighs the risks for you.
- This treatment is not being given in a way that would interfere with other clinical studies testing it for approval.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests ONC206, a new targeted medicine, for diffuse midline gliomas (DMG) with a specific gene change (H3K27 altered) and for some other recurrent brain/spinal cord cancers. It is designed to find the right dose and see whether it can control or shrink tumors after initial treatment or when the cancer returns.
This program provides access to an unapproved drug called nirogacestat for patients with serious conditions who have run out of standard treatment options. It is designed for compassionate use when no other trial is available.
This trial tests a new treatment for recurrent glioblastoma using tiny magnetic particles (nanoparticles) that are heated to kill cancer cells. The particles are injected into the tumor, and then a magnetic field device heats them up. It's for people who have already tried standard therapy and whose tumor has come back.
This trial tests whether adding a NAD+ booster (NMN) to radiation and immunotherapy can help people with advanced lung cancer. It may improve the effectiveness of the treatment and help you live longer.
This study tests a new drug called TUB-040 for people with ovarian cancer that has stopped responding to platinum chemotherapy, or with a type of lung cancer that has returned or spread. The drug is designed to target cancer cells and deliver a powerful anti-cancer agent directly to them, potentially slowing the disease.
This program provides early access to two experimental cancer drugs, botensilimab and balstilimab, for patients with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.